共 50 条
- [1] Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phaseLANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (09): : 748 - 761Pivonello, RosarioFleseriu, MariaNewell-Price, JohnBertagna, XavierFindling, JamesShimatsu, AkiraGu, FengAuchus, RichardLeelawattana, RattanaLee, Eun JigKim, Jung HeeLacroix, AndreLaplanche, AudreyO'Connell, PaulTauchmanova, LibusePedroncelli, Alberto M.Biller, Beverly M. K.
- [2] A randomized, double-blind Phase III study designed to assess the efficacy and safety of pasireotide (SOM230) in patients with Cushing's diseaseENDOCRINE JOURNAL, 2010, 57 : S513 - S513Maldonado, MarioPivonello, RosarioGu, FengSchoenherr, UlrikeSen, KapildebHu, KeColao, Annamaria
- [3] Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitisGUT, 2020, 69 (02) : 224 - 230Xiao, YinglianZhang, ShutianDai, NingFei, GuijunGoh, Khean-LeeChun, Hoon JaiSheu, Bor-ShyangChong, Chui FungFunao, NobuoZhou, WenChen, Minhu
- [4] Long-term efficacy and safety of osilodrostat in Cushing’s disease: final results from a Phase II study with an optional extension phase (LINC 2)Pituitary, 2022, 25 : 959 - 970Maria FleseriuBeverly M. K. BillerJérôme BertheratJacques YoungBetul HatipogluGiorgio ArnaldiPaul O’ConnellMiguel IzquierdoAlberto M. PedroncelliRosario Pivonello
- [5] Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trialLANCET NEUROLOGY, 2019, 18 (04): : 338 - 347Alexandrov, Andrei, VKohrmann, MartinSoinne, LauriTsivgoulis, GeorgiosBarreto, Andrew D.Demchuk, Andrew M.Sharma, Vijay K.Mikulik, RobertMuir, Keith W.Brandt, GordonAlleman, JohnGrotta, James C.Levi, Christopher R.Molina, Carlos A.Saqqur, MaherMavridis, DimitrisPsaltopoulou, TheodoraVosko, MilanFiebach, Jochen B.Mandava, PitchaiahKent, Thomas A.Alexandrov, Anne W.Schellinger, Peter D.
- [6] Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2)PITUITARY, 2022, 25 (06) : 959 - 970Fleseriu, MariaBiller, Beverly M. K.Bertherat, JeromeYoung, JacquesHatipoglu, BetulArnaldi, GiorgioO'Connell, PaulIzquierdo, MiguelPedroncelli, Alberto M.Pivonello, Rosario
- [7] Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathyRMD OPEN, 2020, 6 (03):Baker, MatthewChaichian, YashaarGenovese, MarkDerebail, VimalRao, PandurangaChatham, WinnBubb, MichaelLim, SamHajian, HoomanGurtovaya, OksanaPatel, UptalTumlin, James
- [8] Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY):a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial (vol 397, pg 475, 2021)LANCET, 2021, 397 (10280): : 1182 - 1182Gordon, K. B.Foley, P.Krueger, J. G.
- [9] Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 studyLANCET NEUROLOGY, 2024, 23 (03): : 243 - 255Reilmann, RalfAnderson, Karen E.Feigin, AndrewTabrizi, Sarah J.Leavitt, Blair R.Stout, Julie C.Piccini, PaolaSchubert, RobinLoupe, PippaWickenberg, AnnaBorowsky, BethRynkowski, GailVolkinshtein, RitaLi, ThomasSavola, Juha-MattiHayden, MichaelGordon, Mark Forrest
- [10] Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialLANCET, 2021, 397 (10273): : 475 - 486Gordon, Kenneth B.Foley, PeterKrueger, James G.Pinter, AndreasReich, KristianVender, RonaldVanvoorden, VeerleMadden, CynthiaWhite, KatyCioffi, ChristopherBlauvelt, Andrew